Objective:
To evaluate the efficacy and safety of mivocabtagene autoleucel in adults with antibody-positive stiff person syndrome (SPS) who had responded inadequately to prior immunomodulatory treatment.
Approach:
- Design: Multicenter, open-label phase 2 KYSA-8 trial enrolling 27 adults; 26 received one infusion after low-dose lymphodepleting chemotherapy.
- Assessment: The primary efficacy endpoint was change in the timed 25-foot walk test at week 16. Secondary outcomes included stiffness, hypersensitivity, disability, and mobility; safety and biomarkers were also assessed.
Key Findings:
- At week 16, the median improvement in timed 25-foot walk performance was 45.6%; more than 80% of participants had clinically meaningful improvement in walking speed.
- Eight of 12 participants who initially used walking aids no longer required them.
- Improvements were reported across secondary measures. All 26 treated participants remained off SPS-directed immunomodulatory or immunosuppressive therapy at latest follow-up, which had a median duration of 6.5 months.
- Peripheral B-cell depletion was observed by day five. Among participants with elevated GAD65 autoantibodies, median antibody levels fell 56% by week 16.
- Cytokine release syndrome occurred in 92.3% of participants, all at grade 1 or 2; three had grade 1 neurotoxicity, and five (19.2%) had grade 3 or 4 neutropenia. No deaths or adverse-event-related discontinuations were reported.
Interpretation:
The trial authors reported improvements in mobility and other SPS measures after a single infusion. They stated that long-term follow-up to establish the durability of benefits is in progress.
Limitations:
- The trial was open-label and included 26 treated participants.
- Latest follow-up had a median duration of 6.5 months; durability of benefit remains under investigation.
Sources:
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.